H. Paul Singh, M. D., FACC

H. Paul Singh, M. D., FACC

Appointment
  • (616) 456-9553 or toll-free 888-259-8044
  • Accepting new patients and all insurances
Specialties
  • Cardiovascular Disease
  • Interventional Cardiology
  • Peripheral Vascular Disease
  • Pacemaker and Defibrilator Placement
Board Certifications
  • American Board of Internal Medicine
  • American Board of Cardiology
  • Diplomat – Interventional Cardiology
  • Diplomat – Nuclear Cardiology
Hospitals Served
  • Mercy Health St. Mary’s Campus
  • Metro Health Hospital
  • Spectrum Health Blodgett Hospital
  • Spectrum Health Butterworth Hospital
  • Meijer Heart Center
  • Spectrum Health United Hospital
    (Greenville)
  • Spectrum Health Kelsey Hospital
    (Lakeview)
Languages Spoken
  • English, Punjabi
Education
  • Fellowship – Cardiology
    West Virginia Hospital,
    Morgantown, WV
Residency
  • Prince George’s Hospital Center,
    Cheverly, MD
Medical School (MD)
  • Dayanand Medical College & Hospital,
    Punjab, India
Professional Affiliations
  • Fellow, American College of Cardiology (FACC)
  • American Medical Association
Academic Appointments
  • 2002 – Clinical Faculty,
    Grand Valley State University, Allendale, MI
  • 1992-93 – Instructor, West Virginia University,
    Cardiology Section
  • 1990-93 – West Virginia University
    School of Medicine, Morgantown, WV
  • 1987-90 – Prince George’s Hospital Center,
    Cheverly, MD
Publications & Research
Abstracts
  • Morise AP, Singh HP, Duval R; Evaluation for "Gender Bias in the Post Exercise Test Management of Outpatients with Suspected Coronary Artery Disease", Vol 21, P32A, 1992
  • Singh HP, Morise AP, Duval RD; "Incremental Discrimination of ST Segment Derived Variables in Patients Undergoing Diagnostic Exercise Electrocardiography", Clinical Research; Vol. 40, No. 2, P405A, 1992
  • Singh HP, Schmidt SB, Jain AC; "Effect of Postural Changes on Transmitral Velocity in Myocardial Infarction Patients", Clinical Research; Vol 40, No. 2, P405A, 1992
  • Samdarshi TE, Change LL, Balal RS, Singh HP, Mehta RH, Nath H, Nanda NC; “Transesophageal Color Doppler Echocardiography in Assessing Proximal Coronary Artery Disease".
    JACC; March 1990
  • Singh HP, Avasthi GL, Katyal JC, Aggarwal SP; "Study of Copper, Zinc, Calcium and Magnesium in Chronic Renal Failure"
Papers
  • Samdarshi TE, Nanda NC, Fall RP, Gatewood JR, Ballal RS, Chang LK, Singh HP, Nath HD, Kirklin JE, Pacifico AD;
    "Usefulness and Limitations of Transesophageal Echocardiography in the Assessment of Proximal Coronary Artery Stenosis”.
    JAAC; Vol 19, No. 3, March 1, 1192:572-580
Thesis
  • Singh HP, Avasthi GL, Katyal JC, Aggarwal SP; "Study of Copper, Zinc, Calcium and Magnesium in Chronic Renal Failure".
    Approved M.D. Thesis by Punjab University,
    Chandugarh India 1984
Research
  • H. Paul Singh, Principle Investigator. Measure the incidence of atrial fibrillation within a 12-month follow-up period in pacemaker patients with sick sinus syndrome and no prior history of atrial fib. Sponsor - Guidant
  • H. Paul Singh, Sub Investigator. Angiomax in PTCA. Sponsor – Medicine Company
  • H. Paul Singh, Principle Investigator. Double blind hypertensive study using omapatrilat. Sponsor - Bristol-Myers Squibb
  • H. Paul Singh, Principle Investigator. Double blind study using omapatrilat.
    Sponsor - Bristol-Myers Squibb
  • H. Paul Singh, Principle Investigator. Lipid study using a combination drug of lovastatin and niacin. Sponsor - Kos
  • (Sub-investigator) Use of filter wire in saphenous Vein graft interventions
  • (Sub-investigator) Use of second-generation Filter Wire in saphenous vein graft interventions
  • (Sub-investigator) Prospective, Randomized Trial Evaluating the Slow-Release Formulation of Paclitaxel-Eluting Stent in the Treatment of Coronary Artery Disease
  • (Sub-investigator) Prospective, Randomized Trial evaluating the Slow-Release Formulation of Paclitaxel-Eluting Coronary
    Stent in the Treatment of In-stent Restenosis
  • H. Paul Singh, Principle Investigator. Ezetimibe Add-On to Statin for Effectiveness Trial.
  • (Sub investigator) Clinical Outcomes of the MULTI-LINK MINI VISION RX Coronary Stent System in vessel diameters 2.0 mm to 2.5 mm